# Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma

> **NCT00004123** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Doxorubicin hydrochloride (DOX)
- **PROCEDURE:** Conventional surgery
- **RADIATION:** Intraoperative radiation therapy (IORT)
- **RADIATION:** Radiation Therapy (RT)

## Key facts

- **NCT ID:** NCT00004123
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** 2001-07
- **Final completion:** 2009-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004123, "Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*